Lilly and Biogen are losing money on those mAbs so far - not much incentive for a BP to pursue something that can't be a real blockbuster. US docs are reluctant to Rx and EU countries don't want to pay. That seems like plenty of incentive to stop development of marginal therapies.
"They will never be the effective, low side effect and cheap oral medication that Blarcamasine offers yet they keep dumping billions into chasing the same unicorn over and over."
Reminds me of the days when treatment for stomach ulcers was surgery. Those surgeons (through the AMA) fought for years to stop the antibiotic treatment protocol. Finally they lost...as will be the case for MABs vs Blarcamasine.
Market Data 
Markets 
AI
